Cargando…
The Long-Term Observation of the Beneficial Effects of Treatment: 0.12 mg Anti-VEGF Monotherapy or Anti-VEGF Combined Therapy and Diode-Laser in Various Stages of Retinopathy of Prematurity—Series of Cases
Background 2-year observations of ranibizumab monotherapy and combined therapy with diode laser for severe ROP in extremely prematures. Materials and methods: In a group of 18 prematures (n = 36 eyes; 5 study groups); 25.8 ± 1.5 Hbd, birth weight 796.5 ± 166.1 g. Apgar 4.62 ± 1.88) with A-ROP (n = 2...
Autores principales: | Modrzejewska, Monika, Nazwalska, Martyna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488330/ https://www.ncbi.nlm.nih.gov/pubmed/37685711 http://dx.doi.org/10.3390/jcm12175644 |
Ejemplares similares
-
Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity
por: Hartnett, M. Elizabeth, et al.
Publicado: (2023) -
Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons’ in Hamlet's dilemma?
por: Azad, Rajvardhan
Publicado: (2011) -
Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
por: Linghu, Dandan, et al.
Publicado: (2022) -
Associations of VEGF Polymorphisms With Retinopathy of Prematurity
por: Ling, Xiao Chun, et al.
Publicado: (2023) -
Leukostasis retinopathy treated with Anti-VEGF therapy
por: Shakibai, Nasim, et al.
Publicado: (2020)